// App-Quantinova.ai

183 : PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.

Researchers

Presenter

  • Dirk Schadendorf

Principal Investigators

  • Georgina V. Long

  • Jean Jacques Grob

  • Paul D. Nathan

  • Antoni Ribas

  • Michael A. Davies

  • Keith Flaherty

  • Matthew Squires

  • Savina Jaeger

  • William Powell

  • Puay Tan

  • Caroline Robert

Medical Centers

  • University Hospital of Essen, Essen, Germany

  • Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia

  • Aix Marseille University, Marseille, France

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA

  • Novartis AG, Basel, Switzerland

  • Novartis AG, Basel, Switzerland

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

  • Gustave Roussy Comprehensive Cancer Center, Villejuif, France

Locations

  • Germany

  • Australia

  • France

  • United Kingdom

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Programmed death-ligand 1

Drug/Treatment

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01597908

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved